These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4026268)

  • 21. Cefotetan: profile of in-vitro activity.
    Bauernfeind A
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():19-29. PubMed ID: 6601656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
    Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
    Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
    O'Donnell ED; Freimer EH; Gilardi GL; Raeder R
    Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative inhibitory and bactericidal activities of moxalactam and seven other antibiotics against 520 clinical isolates including 65 multi-drug resistant strains.
    Sutphen NT; Baltch AL; Conroy JV; Hammer MC; Smith RP
    J Antimicrob Chemother; 1982 Jul; 10(1):11-24. PubMed ID: 6213592
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro activity of cefbuperazone against Bacteroides spp.
    Dias MB; Jacobus NV; Gorbach SL; Tally FP
    Antimicrob Agents Chemother; 1985 Jun; 27(6):968-70. PubMed ID: 4026272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
    Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of new cephamycins in the management of obstetric and gynecologic infections.
    Jones RN
    J Reprod Med; 1990 Nov; 35(11 Suppl):1070-7. PubMed ID: 2277375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins.
    Inouye S; Goi H; Watanabe T; Hara T; Miyauchi K; Yoshida T; Kazuno Y; Kadosawa H; Hirano F; Kawaharajo K
    Antimicrob Agents Chemother; 1984 Nov; 26(5):722-9. PubMed ID: 6440478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.
    Reimer LG; Mirrett S; Reller LB
    Antimicrob Agents Chemother; 1980 Mar; 17(3):412-6. PubMed ID: 6448577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.
    Snepar R; Poporad G; Romano J; Levison ME
    Antimicrob Agents Chemother; 1981 Nov; 20(5):642-7. PubMed ID: 6459763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefotetan: comparative study in vitro against 226 Gram-negative clinical isolates.
    Morel C; Vergnaud M; Langeard MM; Dupuy L
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():31-6. PubMed ID: 6573323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of bacterial pathogens to cefotetan judged by MIC and disc tests.
    Grimm H
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():37-43. PubMed ID: 6573324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of in-vitro activity of cefotetan (ICI 156834), a new cephamycin derivative, with that of cefoxitin.
    Chattopadhyay B; Teli JC
    J Antimicrob Chemother; 1982 Aug; 10(2):151-4. PubMed ID: 6956565
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro evaluation of LY127935, a new beta-lactam antibiotic with broad-spectrum activity.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1980 Jul; 6(4):495-8. PubMed ID: 6448833
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.
    Jones RN; Fuchs PC; Barry AL; Gavan TL; Gerlach EH; Sommers HM
    Clin Ther; 1980; 3(Spec Issue):14-23. PubMed ID: 6446389
    [No Abstract]   [Full Text] [Related]  

  • 38. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates.
    Cohn DL; Reimer LG; Reller LB
    J Antimicrob Chemother; 1982 Mar; 9(3):183-94. PubMed ID: 6210653
    [No Abstract]   [Full Text] [Related]  

  • 40. Susceptibility of upper-genital tract isolates from women with pelvic inflammatory disease to ampicillin, cefpodoxime, metronidazole, and doxycycline.
    Hasselquist MB; Hillier S
    Sex Transm Dis; 1991; 18(3):146-9. PubMed ID: 1948511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.